Editas Medicine, Inc. (EDIT)
NASDAQ: EDIT · Real-Time Price · USD
2.880
-0.030 (-1.03%)
At close: Nov 4, 2024, 4:00 PM
2.850
-0.030 (-1.04%)
Pre-market: Nov 5, 2024, 8:00 AM EST

Company Description

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases.

It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia.

In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer.

It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; collaboration and nonexclusive license agreement with Genevant Sciences to develop Novel mRNA-LNP gene editing therapeuticsand strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, as well as collaboration with Bristol Myers Squibb for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases.

The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013.

Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Editas Medicine, Inc.
Editas Medicine logo
Country United States
Founded 2013
IPO Date Feb 3, 2016
Industry Biotechnology
Sector Healthcare
Employees 265
CEO Gilmore O’Neill

Contact Details

Address:
11 Hurley Street
Cambridge, Massachusetts 02141
United States
Phone 617 401 9000
Website editasmedicine.com

Stock Details

Ticker Symbol EDIT
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001650664
CUSIP Number 28106W103
ISIN Number US28106W1036
Employer ID 46-4097528
SIC Code 2836

Key Executives

Name Position
Dr. Gilmore O'Neill M.D. President, Chief Executive Officer and Director
Erick J. Lucera C.F.A., CPA Chief Financial Officer and Executive Vice President
Dr. Linda C. Burkly Ph.D. Executive Vice President and Chief Scientific Officer
Dr. Baisong Mei M.D., Ph.D. Executive Vice President and Chief Medical Officer
Dr. Feng Zhang Ph.D. Co-Founder and Scientific Advisory Board Member
Prof. George McDonald Church Ph.D. Co-Founder and Scientific Advisory Board Member
Gregory Whitehead Executive Vice President and Chief Technical and Quality Officer
Cristi Barnett Corporate Communications and Investor Relations
Charlene Stern J.D., Ph.D. Executive Vice President and General Counsel
Linea Aspesi Executive Vice President and Chief People Officer

Latest SEC Filings

Date Type Title
Nov 4, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 4, 2024 10-Q Quarterly Report
Nov 4, 2024 8-K Current Report
Oct 22, 2024 8-K Current Report
Oct 17, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Oct 4, 2024 8-K Current Report
Aug 29, 2024 144 Filing
Aug 29, 2024 144 Filing
Aug 7, 2024 10-Q Quarterly Report
Aug 7, 2024 8-K Current Report